Sintx Technologies, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsSINTX Technologies is an advanced ceramics company commercializing FDA-cleared silicon nitride medical implants and industrial ceramic components.
What they do
SINTX develops, manufactures, and sells silicon nitride biomaterials, medical devices, and ceramic parts. Its products serve musculoskeletal and antipathogenic applications, as well as electrical, aerospace, and other industrial sectors. The company operates a single reportable segment with manufacturing in Salt Lake City, Utah.
Revenue drivers
- Product revenue (medical and industrial ceramic components) — Revenue from sale of silicon nitride components, coatings, and materials for aerospace, medical device, and other industrial customers. Product revenue was $729K in 2025 and $447K in Q2 2026, up 347% year-over-year.
- Grant and contract revenue — Government agency awards supporting product development. Revenue was $289K in 2025 and $5K in Q2 2026, down 90% year-over-year.
- SiNAPTIC Foot & Ankle Implant System — FDA 510(k) cleared in October 2025. Initial commercial release began in H1 2026 with a network of twelve orthopedic distributors. Revenue generation still early stage.
Recent performance
Total revenue for 2025 was $1.0 million, down 65% from $2.9 million in 2024, driven by a 82% decline in grant and contract revenue. Net loss for 2025 was $10.4 million. In Q2 2026, total revenue was $452K, up 199% from $151K in the prior-year quarter, led by product revenue growth. Gross profit improved to $278K in Q2 2026 versus $57K a year earlier. Cash and equivalents were $3.6 million as of June 30, 2026.
Strategy
SINTX is transitioning from technology development to commercial execution. In H1 2026, it rolled out its SiNAPTIC Foot & Ankle Osteotomy Wedge System through a limited-use release and established a distributor network. The company also raised additional capital and invested in advanced manufacturing capabilities. Management is focused on expanding commercial distribution, building a diversified portfolio across medical and industrial markets, and preserving liquidity through cost measures.
Risks
- Capital constraints — Existing cash and ATM capacity are insufficient to fund all development and commercialization; future funding is required.
- Commercial execution risk — The SiNAPTIC system's market adoption is unproven, and surgeon training and acceptance may take longer than expected.
- Revenue concentration in industrial purchase orders — A $3.2 million order backlog is subject to delivery schedules, customer acceptance, and timing of revenue recognition.
- History of operating losses — The company has incurred losses in each year from 2021 to 2025, and may continue to do so.
Outlook
Management expects total revenue of approximately $900K to $1.1 million in Q3 2026 and $1.0 million to $1.3 million in Q4 2026, based on current production schedules and purchase orders. The outlook is subject to significant uncertainty regarding customer schedules, manufacturing yield, and shipment timing.